SCHEMBL2484318

SCHEMBL2484318

Cc1ccc(C(Cl)(c2ccccc2)c2ccc(C)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.48
ACHE P22303 2/20 0.48
LMNA P02545 2/20 0.48
ALOX12 P18054 1/20 0.48
KIF11 P52732 8/20 0.47
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
XBP1 P17861 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP19A1 P11511 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL118809 1.00 TSHR (0.48) TSHRACHELMNAALOX12KIF11
Chlorotriphenylmethane SCHEMBL29248291 0.92 TSHR (0.58) TSHRACHELMNAALOX12KIF11
SCHEMBL11527250 0.89 TSHR (0.55) TSHRACHELMNAALOX12HPGD
SCHEMBL11588689 0.89 TSHR (0.55) TSHRACHELMNAALOX12HPGD
SCHEMBL12379580 0.88 KIF11 (0.44) TSHRACHELMNAALOX12KIF11
SCHEMBL13379252 0.88 KIF11 (0.40) TSHRACHELMNAALOX12KIF11
SCHEMBL16321127 0.86 ACHE (0.56) TSHRACHELMNAKIF11SMN1; SMN2
SCHEMBL17753724 0.86 KIF11 (0.47) TSHRLMNAKIF11MEN1KMT2A
SCHEMBL12730666 0.86 ACHE (0.56) TSHRACHELMNAKIF11SMN1; SMN2
SCHEMBL7644095 0.85 TSHR (0.48) TSHRACHELMNAALOX12KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115677810-A Double-stranded oligonucleotide, composition containing double-stranded oligonucleotide, conjugate, preparation method and application 苏州瑞博生物技术股份有限公司 2023-02-03 CN disclosed
EP-1970445-B1 METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS RIKEN (JP) 2012-09-26 EP disclosed
US-8207093-B2 Producing libraries; including high salt post translational incubation step THE GENERAL HOSPITAL CORPORATION (US) 2012-06-26 US disclosed
EP-1712623-B1 Selection of proteins using RNA-protein fusions GEN HOSPITAL CORP (US) 2011-10-19 EP disclosed
US-8030478-B2 Method for nucleic acid replication and novel artificial base pairs RIKEN (JP) 2011-10-04 US disclosed
US-7705222-B2 methods, compositions and apparatus for detection, identification and/or sequencing of nucleic acids and/or other biomolecules using nano-barcodes and scanning probe microscopy; high speed of obtaining sequence data, low cost of sequencing, high efficiency in terms of amount of operator time required INTEL CORPORATION (US) 2010-04-27 US disclosed
US-20100036111-A1 METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS RIKEN (JP) 2010-02-11 US disclosed
EP-1151143-B1 SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS GEN HOSPITAL CORP (US) 2009-04-08 EP disclosed
US-7476786-B2 Using nanoparticles to identify and/or sequence biomolecules; forensic analysis; medical diagnostics INTEL CORPORATION (US) 2009-01-13 US disclosed
EP-1970445-A1 METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS Riken (JP) 2008-09-17 EP disclosed
WO-2001002415-A1 C3'-METHYLENE HYDROGEN PHOSPHONATE MONOMERS AND RELATED COMPOUNDS ISIS PHARMACEUTICALS, INC. (US) 2001-01-11 WO disclosed
WO-2001002419-A1 C3'-METHYLENE HYDROGEN PHOSPHONATE OLIGOMERS AND RELATED COMPOUNDS ISIS PHARMACEUTICALS, INC. (US) 2001-01-11 WO disclosed
WO-2000047775-A1 SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS THE GENERAL HOSPITAL CORPORATION (US) 2000-08-17 WO disclosed
CN-1251593-A Selection of proteins using RNA-protein fusions GEN HOSPITAL CORP (US) 2000-04-26 CN disclosed
EP-0971946-A1 SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS THE GENERAL HOSPITAL CORPORATION (US) 2000-01-19 EP disclosed
WO-1998031700-A1 SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS THE GENERAL HOSPITAL CORPORATION (US) 1998-07-23 WO disclosed
EP-0691979-A1 NOVEL 5'-SUBSTITUTED NUCLEOSIDES AND OLIGOMERS PRODUCED THEREFROM SANOFI (FR) 1996-01-17 EP disclosed
WO-1994022890-A1 NOVEL 5'-SUBSTITUTED NUCLEOSIDES AND OLIGOMERS PRODUCED THEREFROM STERLING WINTHOP INC. (US) 1994-10-13 WO disclosed
EP-0083777-A1 Physiologically active peptide with between 147 and 162 amino acid residues Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1983-07-20 EP disclosed
US-4098894-A FUNGICIDES AND BACTERICIDES BAYER AKTIENGESELLSCHAFT (DE) 1978-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100036111-A1 METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS POLM, POLL, POLRMT TSHR 3466/4885ACHE 4828/4885LMNA 3624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.